- Tools for Investors
- Stock News
- Investing Ideas
- Econ & Policy
- Personal Finance
John Heinbockel – Guggenheim Securities: When you think about the progression of generics, how do you think we are going to experience the MACing progression here versus (pair) cycles, and when you look at how generics fall fiscal ’13 versus ’12, ’13 will be bigger, but could it be as big as 50% or 75% big or more balanced than that?
A Closer Look: CVS Caremark Corp Earnings Cheat Sheet>>
Larry J. Merlo – President and CEO: Well, John, I think as we’ve been talking about generics for more than a year now, I think what we’re seeing is it’s performing exactly the way we believe that would and the way we’ve modeled, and we had said that we would maximize profitability for those drugs that had exclusivity period once the 180-day exclusivity period expired. And that’s what we’re seeing with Plavix and with Lipitor. And with drugs like Plavix that do not have an exclusivity period, we’re able to maximize that profitability on day one. I think, again as we acknowledge that during that break-open period where the exclusivity period is no longer in effect while we see MACing increase, we also see significant reductions in cost of goods and that’s what makes it net positive for the business. So we have not seen any surprises from the way we’ve modeled things from an acquisition cost as well as MACing, as well as what we’re seeing in terms of the actual penetration the percent of the brands that have now switched to the generic.
John Heinbockel – Guggenheim Securities: But it is – the impact will be greater in ’13 or now?
Larry J. Merlo – President and CEO: Well, John, I mean we’ll talk more about that as we provide ’13 guidance. Obviously, when we think about the first half of ’13, we’ll be comping up against the exclusivity period of Lipitor, and we’ve just got to model the rest of the year beyond that, and again, we’ll talk more about that as we get closer to provide a ’13 guidance.
John Heinbockel – Guggenheim Securities: All right. And then with respect to front-end, which was actually pretty good, did you see as others have sort of a slowdown toward the end in June specifically, and have you seen any signs of the consumer retrenching? And then so to along with that, what do you think happens promotionally in the back half of the year with respect to the front end; not with Walgreens trying to recover Express business so much, but as they launch their loyalty program, do you think the promotional environment heats up or not so much?
Larry J. Merlo – President and CEO: Yeah, John, let me – the first part of your question, I think that we saw the second quarter get off to a slow start for some of the reasons that we had acknowledged in the prepared remarks in terms of the allergy season being frontloaded, if you will, as well as the Easter comp, and quite frankly, a slow start to the summer selling period as we had a pretty rainy May. So, we saw things improve as we ended up going to the latter part of the quarter. I think the consumer still remains cautious and is looking for value, and as we’ve talked many times, we look to ExtraCare to provide that value in a very differentiated way. I think if you back out the activity associated with the Walgreens Express issue, we see the promotional environment being relatively normal as we move into the second half of year.
John Heinbockel – Guggenheim Securities: There’s really no reason for you to have to respond to their loyalty program, correct? That’s, I would (SAY)?
Larry J. Merlo – President and CEO: Well, John, listen we – again, as we’ve been at the loyalty program for the better part of 15 years, okay, we’ve got tremendous learnings. We’ve got over 70 million active cardholders and we’re not done. We’re continuing to look for ways to enhance value and continue to take ExtraCare to new heights. So, we’re always trying to figure out how we can do that and you see that come to life in the marketplace but in terms of your specific question in terms of do we respond to a competitor introducing a loyalty program, no, we respond to continuing to bring enhancements that add value to our existing program.
Dane Leone – Macquarie Research: Just a question on the PBM side. Can you just remind us how the progression usually goes throughout the year with renewals, retention rates seemed a little lower than how you ended the year last year, is this expected to increase as you complete the remainder of your renewals or are you seeing something different (compatible) the PBM side?
David M. Denton – EVP and CFO: This is Dave. Maybe I’ll start with that. Our retention rate is slightly lower than it was last year as you recall. Larry mentioned it on the call that we had, started the year with a couple of losses. I would say that kind of where we are from a renewal standpoint through this period of the year is fairly consistent with where a typical year would land. So we’re not seeing anything too abnormal there but albeit that retention rate should be, our expectation is that’s probably where they’ll be in the year as well.
Larry J. Merlo – President and CEO: Acknowledging that, that would be slightly less than last year.
Dane Leone – Macquarie Research: Just a point of clarification on a previous remark that you made regarding narrow networks, that 20% was it new clients signed up, what needs to enter into a narrow network excluding Maintenance Choice, if you could just clarify that comment?
David M. Denton – EVP and CFO: That 20% was excluding Maintenance Choice and it was looking at new client revenues.
Per Lofberg – EVP, CVS Caremark Corporation and President, Caremark Pharmacy Services: So, typically, a restricted network is one approach for customers to save money Maintenance Choice is an alternative approach in a way that’s a restricted network too, because for maintenance meds, it dramatically focuses patients on mail order or CVS Retail for maintenance meds. So, both of those are in play with many, many customers currently.
Dane Leone – Macquarie Research: So, this was noted as being an uptick year-over-year, you are seeing an increase amount of interest into entering into narrow networks throughout?
Per Lofberg – EVP, CVS Caremark Corporation and President, Caremark Pharmacy Services: Yes.
Don't miss one of the biggest bull markets in history! Covers Gold, Silver, Gold & Silver stocks, and miners.
There's always a bull market in some sector! Find the best opportunities in commodities.